Topic: Brain and Nerve Health
DRUG DISAPPOINTMENT: After strong results in a midstage study, an Alzheimer's drug Pfizer Inc. is developing with a partner unexpectedly failed to work in a late-stage patient test. WHAT'S NEXT: Scientists at Pfizer and Medivation Inc. will analyze the data to try ...
Shares of Medivation Inc. plunged Wednesday after the failure of Dimebon, an Alzheimer's drug the company is developing with Pfizer Inc. Medivation stock lost about two-thirds of its value and fell to an annual low Wednesday morning. Before the market opened, Medivation and Pfizer said ...
LONDON (Reuters) - New imaging technology suggests an experimental drug for Alzheimer's reduces clumps of plaque in the brain by around 25 percent, lifting hopes for a medicine that disappointed in clinical tests two years ago. Bapineuzumab -- being developed by Pfizer Inc, Irish drugmaker Elan Corp and Johnson & Johnson -- is a potential game-changer because it could be the first ...
